Spero Therapeutics Inc (SPRO) — Titan Protect Analysis

SPRO

Spero Therapeutics Inc

Healthcare · ·

$2.82

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$161M

Total market value of the company

Trailing P/E

10.31

Reasonably valued

Forward P/E

-2.51

Based on estimated future earnings — lower means cheaper

Rev Growth

-95.6%

Year-over-year revenue change

Profit Margin

24.9%

How much profit the company keeps from each dollar of revenue

ROE

35.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+42% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement

https://sperotherapeutics.com

Country: United States Employees: 25 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.621

Good returns relative to risk taken

Kelly Fraction

0.0581

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.697

Acceptable balance between returns and drawdown risk

Annual Return

43.7%

Historical annualised return based on price data

Max Drawdown

-62.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

183

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.43

Moves slightly more than the broader market

52W High

$3.22

12% below the year high

52W Low

$1.80

57% above the year low

Avg Volume

516,453

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.67

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

54.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2,921.7%

Profit from core operations before interest and tax

Free Cash Flow

$13M

Positive — the business generates more cash than it spends

Revenue (TTM)

$61M

Total revenue over the last 12 months

Net Income

$15M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$4.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go